Status:
TERMINATED
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
Lead Sponsor:
NSABP Foundation Inc
Collaborating Sponsors:
Genentech, Inc.
Hoffmann-La Roche
Conditions:
Colorectal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer ce...
Detailed Description
Due to greater patient convenience and favorable toxicity profiles, clinical practice has seen an increased use of the combinations of capecitabine with oxaliplatin (CAPOX) and capecitabine with irino...
Eligibility Criteria
Inclusion
- Pathological diagnosis of colon or rectal cancer from either the colon or rectum or a metastatic site (beyond the colon or rectum)
- Evidence of adequate organ function (such as liver, kidneys, etc.)
Exclusion
- Diagnosis of anal cancer
- Patients who are candidates for surgery
- Patients who have received previous treatments
- Pregnant or lactating women
- History of chronic disease(s) or other serious medical conditions
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00314353
Start Date
March 1 2006
End Date
June 1 2010
Last Update
October 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NSABP Operations Center
Pittsburgh, Pennsylvania, United States, 15212